Related Experiment Video
Updated: Jun 19, 2026
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Integrated Molecular Characterization of Patient-Derived Models Reveals Therapeutic Strategies for Treating CIC-DUX4
Marianna Carrabotta1, Maria Antonella Laginestra1, Giorgio Durante1
1Experimental Oncology Laboratory, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Abstract:
Capicua-double homeobox 4 (CIC-DUX4)-rearranged sarcomas (CDS) are extremely rare, highly aggressive primary sarcomas that represent a major therapeutic challenge. Patients are treated according to Ewing sarcoma protocols, but CDS-specific therapies are strongly needed. In this study, RNA sequencing was performed on patient samples to identify a selective signature that differentiates CDS from Ewing sarcoma and other fusion-driven sarcomas. This signature was used to validate the representativeness of newly generated CDS experimental models-patient-derived xenografts (PDX) and PDX-derived cell lines-and to identify specific therapeutic vulnerabilities. Annotation analysis of differentially expressed genes and molecular gene validation highlighted an HMGA2/IGF2BP/IGF2/IGF1R/AKT/mTOR axis that characterizes CDS and renders the tumors particularly sensitive to combined treatments with trabectedin and PI3K/mTOR inhibitors. Trabectedin inhibited IGF2BP/IGF2/IGF1R activity, but dual inhibition of the PI3K and mTOR pathways was required to completely dampen downstream signaling mediators. Proof-of-principle efficacy for the combination of the dual AKT/mTOR inhibitor NVP-BEZ235 (dactolisib) with trabectedin was obtained in vitro and in vivo using CDS PDX-derived cell lines, demonstrating a strong inhibition of local tumor growth and multiorgan metastasis. Overall, the development of representative experimental models (PDXs and PDX-derived cell lines) has helped to identify the unique sensitivity of the CDS to AKT/mTOR inhibitors and trabectedin, revealing a mechanism-based therapeutic strategy to fight this lethal cancer.
Significance:
This study identifies altered HMGA2/IGF2BP/IGF2 signaling in CIC-DUX4 sarcomas and provides proof of principle for combination therapy with trabectedin and AKT/mTOR dual inhibitors to specifically combat the disease.
Insights
Capicua-double homeobox 4 (CIC-DUX4)-rearranged sarcomas (CDS) are rare, aggressive cancers. Researchers identified a new therapeutic strategy combining trabectedin with PI3K/mTOR inhibitors, showing promise in preclinical models.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Capicua-double homeobox 4 (CIC-DUX4)-rearranged sarcomas (CDS) are rare, aggressive cancers with limited treatment options.
- Current treatments for CDS are based on Ewing sarcoma protocols, highlighting the need for CDS-specific therapies.
Purpose of the Study:
- To identify a molecular signature differentiating CDS from other sarcomas.
- To validate experimental models for CDS research.
- To discover specific therapeutic vulnerabilities and novel treatment strategies for CDS.
Main Methods:
- RNA sequencing of patient samples to identify a CDS-specific gene signature.
- Validation of patient-derived xenografts (PDX) and PDX-derived cell lines as representative CDS models.
- Annotation analysis and molecular validation of differentially expressed genes to identify key signaling pathways.
- In vitro and in vivo efficacy studies of combination therapy.
Main Results:
- A distinct molecular signature was identified for CDS, differentiating them from Ewing sarcoma and other fusion-driven sarcomas.
- An HMGA2/IGF2BP/IGF2/IGF1R/AKT/mTOR signaling axis was identified as characteristic of CDS.
- CDS tumors showed particular sensitivity to combination treatment with trabectedin and PI3K/mTOR inhibitors.
- Combination therapy with trabectedin and the dual AKT/mTOR inhibitor NVP-BEZ235 (dactolisib) demonstrated significant inhibition of tumor growth and metastasis in preclinical models.
Conclusions:
- The development of representative experimental models (PDXs and PDX-derived cell lines) was crucial for this research.
- A mechanism-based therapeutic strategy involving AKT/mTOR inhibitors and trabectedin has been identified for CDS.
- This combination therapy holds promise for treating this lethal cancer.
